Abstract:We have demonstrated previously cell surface receptors for gastrointestinal peptides on 10 human colon cancer cell lines. Because most of the cells studied bind muscarinic cholinergic agonists, we undertook the determination of the cholinergic receptor subtype expressed by human colon cancer cells, as well as the biological function of these receptors, and more specifically, the effect on cell proliferation. We used radiolabeled ligand binding, PCR, calcium mobilization, and cellular proliferation studies. The present study demonstrates a muscarinic cholinergic receptor having two classes of binding site for carbamylcholine. Analysis demonstrated 2499+/-153 binding sites/cell, of which 75% had a high affinity for carbamylcholine (Kd 55 microM), and 25% had a low affinity (Kd 0.33 mM). N-Methylscopolamine, a receptor antagonist, recognized only one binding site having high affinity (Kd 0.20 nM). The number of muscarinic cholinergic binding sites/cell found on colon cancer cells is 50% of the number of receptors found on guinea pig chief cells in physiological conditions. Specific cholinergic receptor antagonists inhibit binding in the following order of potency: N-methylscopolamine > 4-DAMP >> pirenzipine > AF-DX116. This order of potency pharmacologically classifies the receptor as an M3 subtype. Receptor expression, studied by reverse transcription-PCR, correlates with the binding data. Specifically, cell lines that exhibit binding, abundantly expressed the M3 receptor subtype, whereas cell lines that do not exhibit binding for muscarinic cholinergic agonists did not abundantly express the M3 receptor. Agonist activation of the M3 receptor on these cells resulted in intracellular calcium mobilization. The dose-response curve of calcium mobilization suggests that there are spare receptors on these cells. Signal transduction can be inhibited by receptor antagonists in the same order of potency in which the binding is inhibited. Exogenous agonist added to the cells in culture induces significant cell proliferation. These results demonstrate a muscarinic cholinergic receptor of the M3 subtype on human colon cancer cells. This receptor induces intracellular calcium mobilization and mediates cell proliferation. The data suggest that there are spare receptors present, and that there may be enhanced intracellular signal activation in response to receptor binding.

[M3 Muscarnic Receptor Antagonist Mediates Cell Proliferation Apoptosis and Adhesion in Small Cell Lung Cancer].

Modulatory roles of muscarinic cholinergic receptor 3 in proliferation and migration of small cell lung cancer

Muscarinic Cholinergic Receptor Antagonist Inhibits the Growth and Angiogenesis of Small Cell Lung Cancer in Vivo

Distinct roles of cholinergic receptors in small cell lung cancer cells.

Studies on proliferation and migration effects and mechanisms of M3 mAChR in NSCLC cells

Expression of muscarinic cholinergic receptor 3 in small cell lung cancer and its clinical sig-nificance

Blocking M2 Muscarinic Receptor Signaling Inhibits Tumor Growth and Reverses Epithelial-Mesenchymal Transition (EMT) in Non-Small Cell Lung Cancer (NSCLC)

Aclidinium Bromide Holds Promising Inhibitory Effects in A549 Lung Cancer Cells Potentials by Regulating PI3K / AKT Signaling Pathway.

A Novel Muscarinic Antagonist R2hbjj Inhibits Non-Small Cell Lung Cancer Cell Growth And Arrests The Cell Cycle In G0/G1

MEG 3 regulates the invasion and migration of lung cancer via targeting miR-219 a and through MAPK pathway

Effects of M3 muscarinic acetylcholine receptor on alpha smooth muscle-actin expression in cardiac fibroblasts and associated mechanism

Human colon cancer cell proliferation mediated by the M3 muscarinic cholinergic receptor

Muscarinic receptor 3 agonist promotes epithelial-meschymal transition in human lung cancer A549 cells by activating PI3K/AKT signaling pathway

Muscarinic Acetylcholine Receptor M3 Expression and Survival in Human Colorectal Carcinoma—An Unexpected Correlation to Guide Future Treatment?

MUC3A Promotes Non-Small Cell Lung Cancer Progress Via Activating NFκB Pathway and Attenuates Radiosensitivity

Acacetin-induced Cell Apoptosis in Head and Neck Squamous Cell Carcinoma Cells: Evidence for the Role of Muscarinic M3 Receptor.

M3 Muscarinic Acetylcholine Receptors Promote the Survival of H9c2 Cardiomyocytes Through Activating MEK1/2-ERK1/2 Signaling Pathway

High Expression of Muscarinic Acetylcholine Receptor 3 Predicts Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma.

Epididymal Protein 3A is Upregulated and Promotes Cell Proliferation in Non-Small Cell Lung Cancer.

Acetylcholine Acts Through M3 Muscarinic Receptor to Activate the EGFR Signaling and Promotes Gastric Cancer Cell Proliferation

The activation of M3 mAChR in airway epithelial cells promotes IL-8 and TGF-β1 secretion and airway smooth muscle cell migration